Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 354

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Open access
Cutler, Corey, Lee, Stephanie J., Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Lazaryan, Aleksandr, Ramakrishnan, Aravind, DeFilipp, Zachariah, Salhotra, Amandeep, Chai-Ho, Wanxing, Mehta, Rohtesh, Wang, Trent, Arora, Mukta, Pusic, Iskra, Saad, Ayman, Shah, Nirav N., Abhyankar, Sunil, Bachier, Carlos, Galvin, John, Im, Annie, Langston, Amelia, Liesveld, Jane, Juckett, Mark, Logan, Aaron, Schachter, Levanto, Alavi, Asif, Howard, Dianna, Waksal, Harlan W., Ryan, John, Eiznhamer, David, Aggarwal, Sanjay K., Ieyoub, Jonathan, Schueller, Olivier, Green, Laurie, Yang, Zhongming, Krenz, Heidi, Jagasia, Madan, Blazar, Bruce R., Pavletic, Steven · 2021 · Blood

Abstract

Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021012021

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 354

Metadata

Authors
Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R., Wang, T., Arora, M., Pusic, I., Saad, A., Shah, N. N., Abhyankar, S., Bachier, C., Galvin, J., Im, A., Langston, A., Liesveld, J., Juckett, M., Logan, A., Schachter, L., Alavi, A., Howard, D., Waksal, H. W., Ryan, J., Eiznhamer, D., Aggarwal, S. K., Ieyoub, J., Schueller, O., Green, L., Yang, Z., Krenz, H., Jagasia, M., Blazar, B. R., & Pavletic, S.
Venue
Blood
Published
2021-12-02
Volume
138
Issue
22
Pages
2278-2289
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3095621154
Cited by
354
References
32
FWCI
25.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. https://app.cochat.ai/papers/10.1182/blood.2021012021
The paper
Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R., Wang, T., Arora, M., Pusic, I., Saad, A., Shah, N. N., Abhyankar, S., Bachier, C., Galvin, J., . . . Pavletic, S. (2021). Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. https://doi.org/10.1182/blood.2021012021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.